A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
- 25 June 2019
- journal article
- review article
- Published by Elsevier BV in Travel Medicine and Infectious Disease
- Vol. 30, 9-18
- https://doi.org/10.1016/j.tmaid.2019.06.012
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirusJournal of Infection, 2013
- Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapyInternational Journal of Infectious Diseases, 2013
- Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaquesNature Medicine, 2013
- A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild caseInternational Journal of Infectious Diseases, 2013
- Hospital Outbreak of Middle East Respiratory Syndrome CoronavirusNew England Journal of Medicine, 2013
- MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatmentJournal of General Virology, 2013
- Family Cluster of Middle East Respiratory Syndrome Coronavirus InfectionsNew England Journal of Medicine, 2013
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinScientific Reports, 2013
- Cyclosporin A inhibits the replication of diverse coronavirusesJournal of General Virology, 2011
- Small molecules targeting severe acute respiratory syndrome human coronavirusProceedings of the National Academy of Sciences of the United States of America, 2004